Revenue
2019
2020
2021
2022
2023
2024
2025
Ginkgo Bioworks Holdings, Inc. (DNA)
Price—Loading quote
Net income
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $170.2M | $227.0M | $251.5M | $477.7M | $313.8M | $76.7M | $54.2M |
| Research & development | $243.8M | $424.1M | $580.6M | $1.05B | $1.15B | $159.8M | $96.3M |
| Operating expenses | $485.4M | $786.8M | $1.12B | $2.69B | $2.14B | $213.7M | $125.8M |
| Operating income | −$315.3M | −$559.8M | −$864.4M | −$2.21B | −$1.83B | −$137.0M | −$71.6M |
| EBITDAderived | −$256.3M | −$496.7M | −$793.9M | −$2.17B | −$1.80B | −$123.2M | −$60.8M |
| Net income | −$312.8M | −$547.0M | −$892.9M | −$2.10B | −$1.83B | −$126.6M | −$119.3M |
| Basic EPSper diluted share | -$5.64 | -$10.54 | -$18.37 | -$50.15 | -$1.35 | -$0.10 | -$0.10 |
| Diluted EPSper diluted share | -$5.64 | -$10.54 | -$18.37 | -$50.20 | -$1.39 | -$0.10 | -$0.10 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 22, 2026Form 4 | Coen Steven P.See remarks | SellClass A Common Stock | 307 | $8.33 | $2.6K | 50.7K |
| Apr 17, 2026Form 4 | Coen Steven P.See remarks | SellClass A Common Stock | 324 | $7.95 | $2.6K | 50.3K |
| Apr 13, 2026Form 4 | Coen Steven P.See remarks | SellClass A Common Stock | 33.2K | $6.41 | $212.6K | 49.8K |
| Apr 10, 2026Form 4 | Canton BarryTenPercentOwner | SellClass A Common Stock · indirect | 124.7K | $6.43 | $802.0K | 436.4K |
| Apr 10, 2026Form 4 | Shetty Reshma P.See remarks | SellClass A Common Stock | 124.7K | $6.43 | $802.0K | 436.4K |